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Abstract: The 2018 West Nile Virus (WNV) season in Europe was characterized by an extremely high
infection rate and an exceptionally higher burden when compared to previous seasons. Overall, there
was a 10.9-fold increase in incidence in Italy, with 577 human cases, 230 WNV neuroinvasive diseases
(WNNV) and 42 WNV-attributed deaths. Methods: in this paper we retrospectively reported the
neurological presentation of 7 patients admitted to University Hospital of Udine with a diagnosis
of WNNV, especially focusing on two patients who presented with atypical severe brain stem
involvement. Conclusions: the atypical features of some of these forms highlight the necessity to
stay vigilant and suspect the diagnosis when confronted with neurological symptoms. We strongly
encourage clinicians to consider WNNV in patients presenting with unexplained neurological
symptoms in mild climate-areas at risk.
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1. Background
West Nile Virus (WNV) is a positive stranded RNA Flavivirus. It has an enzoonotic cycle among birds
and mosquitos, and can be rapidly spread to several hosts, including humans. WNV infection in humans
might have a wide variety of presentations. In the majority of the cases, it is completely asymptomatic.
A minority of the infected subjects develop symptoms, which range from fever, headache,
gastrointestinal discomfort, skin rash, to serious neurological disorders.
The 2018 West Nile Virus (WNV) season in Europe was characterized by an earlier start and an
exceptionally higher burden when compared to previous seasons [1,2]. Overall, in 2018, 1605 cases of
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WNV infections were reported in Europe. Italy was the most-affected country, accounting for 39% of
the locally acquired infections. Overall, there was a 10.9-fold increase in incidence when compared
to 2014–2017 seasons, and a 12-fold increase in comparison to 2017. Infection rates per 100,000
population increased from 0.1 (in 2017) to 1.0 in 2018. Overall, t577 human cases were reported in Italy;
WNV neuroinvasive diseases (WNNV) were reported in 230 cases, WNV-attributed deaths were 42.
The majority of the infections were from the Veneto, Emilia-Romagna, Lombardia, Piemonte, Sardegna
and Friuli Venezia Giulia (FVG) regions [3]. In the FVG region, located in the Northeastern corner of the
country, more than 60 WNV infections were reported, including 35 probable and 25 confirmed cases.
Among these, nine cases presented as WNNV, and four had a lethal outcome.
The aim of this report is to describe the neurological presentation of seven patients admitted to
University Hospital of Udine with a diagnosis of WNNV. We focus on two patients who presented
with an atypical manifestation. Table 1 summarizes our clinical experience.
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Abbreviations—rt-PCR: reverse-transcription polymerase chain reaction, IgM: immunoglobulin M, IgG;
immunoglobulin G; IVIG: intravenous immunoglobulin; CSF: cerebrospinal fluid; CMV: cytomegalovirus; VZV:
varicella zoster virus. * Only positive results are reported.
2. Case 1
An 87-year-old man was admitted to Cardiology Intensive Care Unit on August 2018 for
non-ST-segment-elevation myocardial infarction. His prior history was remarkable for ischemic
cardiomyopathy and arterial hypertension. No invasive procedure was performed during the
hospitalization. On day 3, the patient presented abrupt onset of fever, meningeal syndrome, generalized
stiffness and diffuse neuropathic pain. He was alert and oriented and showed no focal deficit. His blood
exams showed leucopenia (3580/mmc white blood cells (WBC)), thrombocytopenia (47,000 platelets/µL)
and elevation of liver enzymes (aspartate aminotransferase (AST) 95 UI/L, alanine aminotransferase
(ALT) 80 UI/L). The cerebrospinal fluid (CSF) was clear and showed hypoglycorrhachia (25%),
hyperproteinorrachia (637 g/L) and hypercellularity (85 cells/µL, 48% polymorphonuclear). Gram stain,
culture and serologic tests for common neurotropic viruses were negative. Brain magnetic resonance
imaging (MRI) showed no abnormalities. Laboratory diagnosis of WNV infection was accomplished
through biologic fluids testing for WNV- specific IgG and IgM antibodies, and reverse-transcription
polymerase chain reaction (rt-PCR). Patient n.1 was tested positive for WNV rt-PCR on serum and
blood, and specific IgM and IgG were found in both CSF and serum. A 5-day course of intravenous
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immunoglobulin (IVIG) at 0.4 g/kg/day and high-dose steroid therapy (500 mg/day for 2 days followed
by 1 mg/kg/day with progressive de-escalation) were administered. The patient’s general status
slowly improved. On day 10, the patient experienced an abrupt neurologic deterioration; he was
found unconscious, with a Glasgow Coma Scale (GCS) of 3. Any organic cause of encephalopathy
was excluded; his blood tests, head computed tomography (CT) scan, electrocardiogram (ECG) and
electroencephalography (EEG) were inconclusive. CSF was checked again and showed residual
cellularity (24 cells/mmc, 60% lymphocytes, 30% polymorphs). The patient was intubated and admitted
to the intensive care unit (ICU). A few hours later, he spontaneously recovered and was extubated.
During the next 2 weeks of hospitalization, the patient manifested three other similar episodes of
“intermittent coma”. A conservative management was performed. He experienced a partial recovery
and was discharged.
3. Case 2
A 57-year-old man with an autoimmune glomerulonephritis (being treated with steroids and
mycophenolate) presented to the emergency department, with a history of three days of fever, confusion,
diplopia, opsoclonus, multifocal myoclonus and generalized tremor. Blood exams and CT scan were
unremarkable. Lumbar puncture revealed normal opening pressure, and the CSF analysis identified
12 cells/µL (30% polymorphonuclear, 60% lymphocytes), protein count of 200 g/L and glucose count
of 70 mg/dL. The EEG showed slow bilateral diffuse slow waves. A presumptive diagnosis of
rhombencephalitis with opsoclonus-myoclonus syndrome was made, and an empirical therapy with
ampicillin, ceftriaxone, acyclovir and dexamethasone was started. Contrast enhanced brain magnetic
resonance imaging (MRI) revealed no acute process or abnormality. During the hospitalizations,
the patient’s condition worsened. He progressively became comatose (GCS of 4) and required ICU
admission and mechanical ventilation. The laboratory documented the presence of WNV-RNA in CSF,
urine and blood samples, and WNV-specific immunoglobulin M (IgM) in blood. Therefore, high doses
of IVIGs and steroids were administered. On day 4, fixed bilateral mydriasis appeared. A CT scan
showed massive intraparenchymal hemorrhage associated with fourth ventricle compression and
tonsillar herniation. The following day, the patient expired. Post-mortem macroscopic examination of
the brain showed diffuse malacia.
4. Discussion
WNV transmission season 2018 has been characterized by an extremely high infection rate.
Overall, 2083 autochthonous infections were reported in 2018 in Europe, with an increase of 7.2-fold
when compared to 2017 [1,2].
WNV diagnosis is mainly formulated by detecting specific IgM and IgG antibodies directed
towards WNV, or by testing for viral nucleic acid in CSF, tissue, blood, or other body fluid. Evidence
of IgM in CSF is the cornerstone of the WNV diagnosis because IgM does not cross the blood
brain barrier. Nevertheless, serology has some pitfalls: IgM remains detectable for 2 to 12 months.
Furthermore, the usual serological enzyme-linked immunosorbent assay (ELISA) may cross-react with
other flavivirus infections or vaccination. There is a great variety of serological methods, but none of
these provide a definitive diagnosis.
Nevertheless, any positive result requires a confirmation with more specific tests. Thus, when IgM
are found positive, seroconversion (by subsequent convalescent sample testing, hemagglutination
inhibition, IgG ELISA, or plaque reduction neutralization assay) should be demonstrated [4].
However, IgM and IgG testing might be insufficient in some cases. Antibodies might not be
present during the window period, as to cause a delay in the diagnosis. Furthermore, special categories,
such as immunocompromised patients, might not be able to mount an adequate serological response.
In this setting, molecular testing for WNV could be useful; however it is known that viremia is
generally rapidly vanishing, and lasts between 3 and 14 days. Prolonged viremia has been reported in
immuno-compromised patients [5].
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Several studies demonstrated that WNV RNA determination in whole blood shows higher
reliability compared to other samples [6,7]. Detection of WNV in urine is not included in the current
case definition of WNV disease postulated by the European Centers for Disease Control. Although
WNV viral load in CSF and blood is usually transient, shedding in the urine can continue for longer
periods after the acute phase [8]. Indeed, the US Centers for Disease Control guidelines have included
the detection of RNA in body fluids other than blood and LCR, including viruria, in the diagnostic
criteria for WNV diagnosis confirmation [9].
Furthermore, pathology may reveal peculiar histological pictures. Autopsy reports have shown
perivascular lymphoplasmacytic infiltrates, both in leptomeninges and parenchyma, microglial nodules
or acute neuronal necrosis. Inflammation generally involves deep nuclei, the cerebellum and brainstem,
with neuronal loss and neuronophagia. In our cases, WNV was present in brain matter, a finding that
suggests a strong correlation between its neurotropism with the distribution of the cerebral lesions [10].
Most WNV infections are usually asymptomatic; 30% of cases present with a febrile illness
characterized by mild symptoms that typically last up to a week. Less than 1% of infections present
with central nervous system involvement [11]. We reported two WNV cases consistent with severe
brain stem involvement. Although there was no electrophysiological or neuroradiology evidence,
both patients presented symptoms due to brainstem and basal ganglia damage. Case 1 showed
neuropsychiatric disorder and loss of consciousness with no apparent organic explanation. Case 2
presented unique findings consistent with opsoclonus-myoclonus syndrome (OPS) complicated with a
massive hemorrhagic stroke. To our knowledge, 14 cases of WNNV-related OPS have been reported to
date [12,13]. The majority of the cases were reported among patients affected by neoplasm or immune
system deficit, as well as our case. Confusion and delirium, which were the main presenting symptoms
in patient n.2, were reported in 30% of the cases, usually after hospital admission. Overall, no specific
MRI findings were described in WNV associated-OPS. However, brainstem infectious involvement
has been speculated to cause secondary cortical hypoperfusion and subsequent dysfunction [14].
Overall, WNV-associated CNS vascular events are rare [12,15,16]. The main hypothesis regarding
the pathophysiology of these events is an inflammatory vasculopathy secondary to WNV CNS invasion.
It has been suggested that WNV reaches CNS through two different routes: spreading within the axons
of peripheral nerves to CNS, and via the blood system. A number of in vitro analyses demonstrated that,
similarly to other flaviviruses, WNV can directly infect the endothelial cells. Once penetrated in
the CNS, WNV elicit complex immunitary responses, which involve both intrinsic CNS immune cells
(microglia and astrocytes) and extrinsic defenses (T cells, B cells, and monocytes/macrophages), thereby,
leading to cytokines release, perivascular inflammation, and neuronal proliferation [17–19]. This could
provide an explanation of the WNV-related vasculitis.
Treatment for WNV infection is mainly supportive. No therapy has been proven useful in a randomized
controlled trial. Few reports and preclinical studies suggest the utility of immunomodulation through IVIG,
plasmapheresis, WNV-specific neutralizing antibodies, corticosteroids, ribavirin, interferon or other RNA
inhibitors [14].
5. Conclusions
The 2018 West Nile outbreak in FVG has been characterized by extraordinary high rates of WNV
infections. The atypicality of the presentation of some of the WNNV forms highlights the necessity to
stay vigilant and suspect the diagnosis when confronted with neurological symptoms. Given that no
treatment has shown real efficacy, there is no consensus about the appropriate treatment. With regards
to all the mosquito-borne infections, prevention measures, including personal protection and mosquito
control programs, are necessary.
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